Zheng Zhenda, Wu Bingyuan, Chen Qian, Luo Yanting, Tang Xixiang, Wang Jiafu, Xie Xujing, Dong Ruiming, Li Weiqiang, Zhu Jieming, Li Suhua
Department of Cardiovascular Medicine, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
VIP Medical Service Center, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Ann Transl Med. 2022 Feb;10(4):170. doi: 10.21037/atm-21-6973.
Coronary sinus (CS) blood sampling gives an insight into the localized pathophysiology of heart diseases. However, additional specifically-designed or modified catheters were needed in most previous studies, making the convenience of clinical application unsatisfactory. This study aimed to introduce a simple method for CS blood sampling without using additional catheters during catheter ablation (CA) of arrhythmias, and to investigate its feasibility and safety.
A total of 119 patients undergoing CA were prospectively enrolled, including 25 with paroxysmal supraventricular tachycardia (PSVT), 30 with premature ventricular complexes (PVC), and 64 with atrial fibrillation (AF). Cannulation and sampling of CS was performed via the femoral vein using a conventional 8F SR0 or 8.5F SL1 introducer sheath (St. Jude Medical) guided by a 6F steerable diagnostic catheter (St. Jude Medical). The success rate and any suspicious complications were recorded. Untargeted liquid chromatograph-mass spectrometer (LC-MS)-based metabonomics of CS samples versus peripheral venous samples were also performed.
CS blood samples were successfully collected from 114 patients, with an overall success rate of 95.8%. Among patients with different arrhythmias, the success rates were similar, with 96.0% in PSVT, 96.7% in PVC, and 95.3% in AF (P=0.223). Adverse events occurred in four (3.4%) patients, including two patients with occasional atrial ectopic beats without causing any discomfort, and two patients with new-onset paroxysmal AF lasting for about 2 min. No serious complications were noted. Metabonomics analysis showed that CS samples provided a number of different metabolites (93 in PVST, 217 in PVC, and 109 in AF) versus peripheral samples.
Our method for CS blood sampling during CA is feasible and safe, and can provide useful cardiometabolic information that is significantly different from a peripheral sample.
冠状窦(CS)采血有助于深入了解心脏病的局部病理生理学。然而,大多数先前的研究需要额外的专门设计或改良导管,使得临床应用的便利性不尽人意。本研究旨在介绍一种在心律失常导管消融(CA)期间无需使用额外导管进行CS采血的简单方法,并探讨其可行性和安全性。
前瞻性纳入119例行CA的患者,包括25例阵发性室上性心动过速(PSVT)、30例室性早搏(PVC)和64例心房颤动(AF)患者。在6F可操纵诊断导管(圣犹达医疗公司)引导下,使用传统的8F SR0或8.5F SL1导入鞘(圣犹达医疗公司)经股静脉进行CS插管和采血。记录成功率及任何可疑并发症。还对CS样本与外周静脉样本进行了基于非靶向液相色谱 - 质谱联用(LC - MS)的代谢组学分析。
114例患者成功采集到CS血样,总体成功率为95.8%。在不同心律失常患者中,成功率相似,PSVT为96.0%,PVC为96.7%,AF为95.3%(P = 0.223)。4例(3.4%)患者发生不良事件,包括2例偶发房性早搏但未引起任何不适的患者,以及2例新发阵发性AF持续约2分钟的患者。未观察到严重并发症。代谢组学分析表明,与外周样本相比,CS样本提供了许多不同的代谢物(PSVT中有93种,PVC中有217种,AF中有109种)。
我们在CA期间进行CS采血的方法可行且安全,并且可以提供与外周样本有显著差异的有用心脏代谢信息。